Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference

Rhea-AI Summary

Kezar Life Sciences, a clinical-stage biotechnology company listed on Nasdaq (KZR), announced that its CEO, Chris Kirk, will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 5, 2024, at 12:30 pm ET in New York. The company focuses on developing novel small molecule therapeutics for immune-mediated diseases and cancer. The event will be webcasted live and available on Kezar's website for 90 days post-event.

Positive

• Participation in Jefferies Global Healthcare Conference increases visibility among investors and stakeholders.
• Webcast availability enhances accessibility for broader audience engagement.
• Focus on developing novel treatments for immune-mediated diseases and cancer meets high unmet medical needs.

Negative

• No new financial or clinical data updates provided in the announcement.
• The press release does not mention any immediate, concrete business or financial gains from the conference participation.
• Potential market reaction could be due to the lack of substantial updates.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer, today announced that Chris Kirk, Co-founder and Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024, at 12:30 pm ET in New York, NY.

A webcast of the panel discussion will be available on the “Events & Presentations” section of the Company’s website at www.kezarlifesciences.com. Following the event, an archived webcast will be available on the Kezar website for 90 days.

About Kezar Life Sciences

Kezar Life Sciences is a clinical-stage biopharmaceutical company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer. Zetomipzomib, a selective immunoproteasome inhibitor, is currently being evaluated in a Phase 2b clinical trial for lupus nephritis and a Phase 2a clinical trial for autoimmune hepatitis. This product candidate also has the potential to address multiple chronic immune-mediated diseases. Kezar’s oncology product candidate, KZR-261, targeting the Sec61 translocon and protein secretion pathway, is being evaluated in an open-label dose-escalation Phase 1 clinical trial to assess safety, tolerability and preliminary tumor activity in solid tumors. For more information, visit www.kezarlifesciences.com, and follow us on LinkedIn, Facebook, Twitter and Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240529724497/en/

Investor and Media Contact:

Gitanjali Jain

Vice President, Investor Relations and External Affairs

Kezar Life Sciences, Inc.

gjain@kezarbio.com

Source: Kezar Life Sciences, Inc.

FAQ

When will Kezar Life Sciences participate in the Jefferies Global Healthcare Conference?

Kezar Life Sciences will participate in the Jefferies Global Healthcare Conference on June 5, 2024, at 12:30 pm ET.

What is the focus of Kezar Life Sciences?

Kezar Life Sciences focuses on developing novel small molecule therapeutics to treat immune-mediated diseases and cancer.

Where can I watch the Kezar Life Sciences panel discussion at the Jefferies Global Healthcare Conference?

The webcast of the panel discussion will be available on the 'Events & Presentations' section of Kezar's website.

How long will the archived webcast of Kezar Life Sciences' fireside chat be available?

The archived webcast will be available on Kezar's website for 90 days following the event.

Who will represent Kezar Life Sciences at the Jefferies Global Healthcare Conference?

Chris Kirk, the Co-founder and Chief Executive Officer of Kezar Life Sciences, will participate in the fireside chat.